Comparative Pharmacology
Head-to-head clinical analysis: CUBICIN versus FORBAXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUBICIN versus FORBAXIN.
CUBICIN vs FORBAXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cubicin is a lipopeptide antibiotic that binds to bacterial cell membranes, causing rapid depolarization and inhibition of protein, DNA, and RNA synthesis, leading to bacterial cell death.
FORBAXIN is a prodrug of the active moiety cefditoren, a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
4-6 mg/kg IV once daily for complicated skin infections; 6 mg/kg IV once daily for Staphylococcus aureus bloodstream infections (including right-sided endocarditis); infuse over 2 minutes or 30 minutes.
IV: 500 mg every 12 hours, infused over 30 minutes.
None Documented
None Documented
Terminal elimination half-life is about 8-9 hours (mean 8.1 hours) in patients with normal renal function; prolonged to 27-35 hours in severe renal impairment (CrCl <30 mL/min).
8-12 hours; prolonged in renal impairment (up to 24 hours in severe cases)
Renal excretion of unchanged drug accounts for approximately 80% of the administered dose; minor fecal excretion (<5%) via biliary elimination.
Renal (60-70% unchanged), biliary/fecal (20-30%)
Category C
Category C
Antibiotic
Antibiotic